Pangaea Oncology, S.A.

Pango operates with a current liquidity position that is moderate, as indicated by a current ratio of 1.87, which is below the typical threshold of 2 for strong liquidity. The company's liquidity is further constrained by a negative net cash position after subtracting total debt, signaling potential short-term financial stress. The debt-to-equity ratio of 0.2 suggests a relatively conservative capital structure, with a low proportion of debt relative to equity.

In terms of profitability, Pango is currently unprofitable, with a net loss of EUR -1,166,590 and an operating loss of EUR -1,693,850. The return on equity (ROE) is -5.28%, and the return on assets (ROA) is -3.6%, both of which are significantly below the industry median for biotechnology and medical research firms. These metrics indicate that the company is not generating returns that meet the cost of capital or industry expectations.

Pango's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks, particularly in the healthcare diagnostics sector, which is subject to regulatory and reimbursement pressures.

The company's growth trajectory is uncertain, with a recent revenue of EUR 14,270,060, which is below the mean analyst estimate of EUR 18,400,000. The operating cash flow is negative at EUR -4,565,090, and the free cash flow is only EUR 839,200, indicating limited capacity for reinvestment or debt servicing. The capital expenditure of EUR -519,880 suggests some investment in infrastructure, but the scale is modest relative to the company's overall financial position.

Pango faces several risk factors, including liquidity constraints and the potential for dilution, although the latter is currently assessed as low. The company's negative net cash position and operating losses raise concerns about its ability to sustain operations without additional financing. The risk assessment highlights the need for close monitoring of the company's cash flow and debt management strategies.

Recent events, including the publication of the latest financial results and analyst estimates, indicate that the company is underperforming relative to expectations. The mean EPS estimate of -0.03 EUR is higher than the actual EPS of -0.10 EUR, suggesting a widening gap between performance and analyst forecasts. The mean EBIT estimate of -700,000 EUR also indicates a continued expectation of operating losses.